Mastocytosis
Authors:
- 1 June 2010
- book chapter
- Published by S. Karger AG
- Vol. 95 (5) , 110-124
Abstract
It is known that patients with mastocytosis have an increased risk of anaphylaxis. This also appears to be the case with patients with evidence of a clonal mast cell disorder resulting in the monoclonal mast cell activation syndrome (MMAS) who do not express the full mastocytosis phenotype. Most patients with mastocytosis are recognized by their characteristic skin lesions. An increased level of baseline serum mast cell tryptase is also an indicator for a possible clonal mast cell disorder including mastocytosis. Other markers for mast cell clonality and for mastocytosis include abnormal immunostaining of mast cells with CD25 and CD2, clustering of mast cells in tissues, abnormal mast cell morphology, and the presence of a mutation in the proto-oncogene c-kit encoding for the mast cell growth receptor KIT. As recognition depends on an understanding of mastocytosis, and this disease should be considered in patients with recurrent anaphylaxis, we describe the features of mast cell clonality, MMAS and mastocytosis, and review recent findings.Keywords
This publication has 41 references indexed in Scilit:
- The biology of Kit in disease and the application of pharmacogeneticsJournal of Allergy and Clinical Immunology, 2004
- NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc RI aggregationBlood, 2004
- Urticaria pigmentosaImmunology and Allergy Clinics of North America, 2004
- A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibBlood, 2004
- Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kitExperimental Hematology, 2003
- Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathologyJournal of the American Academy of Dermatology, 2003
- Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.Proceedings of the National Academy of Sciences, 1995
- Altered Metabolism of Mast-Cell Growth Factor (c-kit Ligand) in Cutaneous MastocytosisNew England Journal of Medicine, 1993
- Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital.1991
- Systemic mast cell disease. Analysis of 58 cases and literature review.1988